Impact of gonadotropin selection on risk of ovarian hyperstimulation syndrome in predicted high responders: a Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer-High Responder trial analysis.

ABSTRACT:

Objective

To evaluate the risk of ovarian hyperstimulation syndrome (OHSS) with highly purified human menopausal gonadotropin (HP-hMG) or recombinant follicle-stimulating hormone (rFSH) for controlled ovarian stimulation in patients predicted to be high responders.

Design

Post hoc analysis of a randomized, open-label, assessor-blind, parallel-group, noninferiority trial conducted at 31 US fertility centers.

Subjects

620 women with serum anti-Müllerian hormone (AMH) ≥5 ng/mL.

Intervention

Controlled ovarian stimulation with HP-hMG or rFSH in a gonadotropin-releasing hormone antagonist assisted reproductive technology cycle. Human chorionic gonadotropin trigger and fresh transfer of a single blastocyst was performed unless ovarian response was excessive; in this

SUBMITTER: Foulk R 

PROVIDER: S-EPMC12496443 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature